IP-PA1 |
|
Vaxjo ID |
302 |
|
Vaccine Adjuvant Name |
IP-PA1 |
|
Adjuvant VO ID |
VO_0005636
|
|
Description |
An immunopotentiator from Pantoea agglomerans, identified as Pantoea agglomerans LPS, which demonstrated anti-inflammatory effects and an inhibitory effect on atopic dermatitis (AD) skin lesions in NC/Nga mice. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
Pantoea agglomerans LPS (immunopotentiator from Pantoea agglomerans 1: IP-PA1) has been reported to have anti-inflammatory effects in in vitro and in vivo models. |
|
Structure |
Lipopolysaccharides (LPS) |
|
Preparation |
The study mentions orally administering 0.1% (High) or 0.01% (Low) water-containing IP-PA1 to mice. |
|
Dosage |
0.1% (High) or 0.01% (Low) water-containing IP-PA1, orally administered to mice. |
|
Function |
Type: microbial derivative vaccine adjuvant. Target Receptor: toll-like receptor 4 (TLR4). Th1-biased immune profile. Pantoea agglomerans LPS (immunopotentiator from Pantoea agglomerans 1: IP-PA1) has been reported to have anti-inflammatory effects in in vitro and in vivo models. The aim of the present study was to investigate the effects of orally-administered IP-PA1 on atopic dermatitis (AD) symptoms induced by Dermatophagoides farinae body extract (DFE) in NC/Nga mice |
|
Safety |
The paper reports observed effects in a mouse model but does not provide a comprehensive safety profile for humans. |
| References |
Wakame et al., 2015: Wakame K, Komatsu K, Inagawa H, Nishizawa T. Immunopotentiator from Pantoea agglomerans Prevents Atopic Dermatitis Induced by Dermatophagoides farinae Extract in NC/Nga Mouse. Anticancer research. 2015; 35(8); 4501-4508. [PubMed: 26168493].
|
